Equillium Inc., a clinical-stage biotechnology company dedicated to developing novel therapeutics for severe autoimmune and inflammatory disorders, took part in the annual meeting of The American Association of Immunologists, IMMUNOLOGY2024, as they showcased their research findings. The meeting, which occurred from May 3 to May 7, was held at McCormick Place Convention Center in Chicago, Illinois.
Equillium was given an opportunity to present a research poster, the contents of which cast a spotlight on new discoveries related to CD6, a cell surface receptor that plays crucial roles in adaptive immune responses. The highlight was the brick and mortar association of CD6 with cellular adhesion and migration.
Cell adhesion, the process through which cells interact and attach to a surface, neighboring cells or extracellular matrix, is a crucial factor in inflammatory responses. Cell migration, on the other hand, is essential not only for inflammatory responses but also for embryonic development, cell growth, and healing processes. Therefore, understanding the factor that contributes to these functions can play a significant role in the creation of therapeutics for various disorders regarding autoimmunity and inflammation.
Diving into the particulars of their current research findings, Equillium provided evidence that CD6 plays an essential role in cell adhesion and migration. Shedding light on the mechanics of the cellular processes can open new pathways for understanding how the immune system works. Ultimately, this understanding can inform the development of potential therapeutic interventions for diverse severe autoimmune and inflammatory disorders.
Equillium’s commitment to bringing scientific clarity to these complex processes underscores its dedication to advancing human health by creating novel treatments. The company’s participation in high-profile gatherings such as IMMUNOLOGY2024, highlights the importance of their work in moving the field forward.
Comments